Novo Nordisk has announced that the Japanese Ministry of Health, Labour and Welfare has approved Rybelsus (oral semaglutide), the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) in
Nordic Life Science
NLS Pharma News
Pharma
Lipigon Pharmaceuticals has attracted SEK 16.6 Million in a new share issue that will help it get nearer to its goal of reducing the number of global deaths caused by
AstraZeneca’s Selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1). Selumetinib is co-developed and co-commercialised with MSD. “Neurofibromatosis type 1 can
Oncopeptides has agreed with Kancera to take over Kancera’s drug development facility in Solna, Sweden. The agreement is an important step in the development of Oncopeptides’ pre-clinical operations and marks
Nordic Nanovector has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for investigating Betalutin for the treatment of adult patients with relapsed or refractory
Zelluna Immunotherapy has announced a research collaboration agreement with Lion TCR (Singapore). The collaboration will focus on the development of TCR-NK products for the treatment of virally induced cancers. “This
Clinical trials
Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed that AZD1222 was tolerated and generated
Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically
GeNeuro enrolls first patient in temelimab Phase 2 multiple sclerosis trial in collaboration with the Karolinska Institutet’s Academic Specialist Center
Nordic Nanovector will amend the trial protocol for its PARADIGME trial to broaden the inclusion criteria and expand the pool
Gesynta Pharma reports positive Phase I results with its lead candidate GS-248 for microvascular disease. Results from the completed First-in-Human
Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analogue. In
Oncopeptides has announced that the full top-line results from the phase 2 HORIZON study, evaluating intravenous melflufen in combination with
Immunicum has announced that the sixth patient has completed the safety period in the ongoing Phase Ib/II ILIAD combination trial
Affibody has announced the completion of the ABY-039 Phase 1 trial, and the termination of the ABY-039 program due to
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to
AlzeCure Pharma has received positive results from the first clinical study with ACD856, aiming to evaluate half-life in humans. ACD856
Follicum has announced that the clinical Phase IIa study with a cream-like formulation of FOL-005 will re-start, following a pause due
BerGenBio has announced that dosing has commenced in the Phase II clinical trial assessing bemcentinib in hospitalized COVID-19 patients. Bemcentinib
The pharma company has lately announced several encouraging results from its ongoing clinical trials in lung cancer, gastric cancer, colorectal
Oncopeptides has announced completion of enrollment in the phase 3 study OCEAN for the treatment of relapsed refractory multiple myeloma.
The Swedish life science industry organization SwedenBIO has released its Drug Discovery and Development Pipeline report, highlighting the state of the
Profiles in Pharma
InDex Pharmaceuticals recently announced conclusions from its CONDUCT study, evaluating their TLR9 agonist cobitolimod for the treatment of moderate to
BioArctic’s lead compound has the potential to become the first disease-modifying treatment for Alzheimer’s, and so far the company’s journey
Few companies are as synonymous with Sweden as AstraZeneca and few CEOs as visible. Yet, Katarina Ageborg, AstraZeneca Sweden’s new
She joined LEO Pharma by chance, more than 27 years ago, but she remained there, for the true focus on
“It is with great regret and sadness we announce this very tragic and unexpected information,” says the Board of Directors,
In an interview in Nordic Life Science, the Head of AstraZeneca’s Oncology Business unit, shared his insights on current drug
Logistics
The best pharmaceuticals and medical supplies on the market are useless to patients unless they arrive at their destinations intact, unspoiled and on time. The proper packaging and shipping of
Two global life science firms share some of their projects and logistical solutions to deliver healthcare to parts of the world where it is needed the most. Cardiovascular disease is